Ventures Iv, L.P.5 Am Co In... Net Worth

The estimated Net Worth of Ventures Iv, L.P.5 Am Co In... is at least 21.7 百万$ dollars as of 16 June 2020. Ventures In owns over 140,000 units of Aprea Therapeutics stock worth over 1,009,460$ and over the last 5 years Ventures sold APRE stock worth over 20,669,000$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures In APRE stock SEC Form 4 insiders trading

Ventures has made over 3 trades of the Aprea Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Ventures sold 140,000 units of APRE stock worth 4,662,000$ on 16 June 2020.

The largest trade Ventures's ever made was selling 255,000 units of Aprea Therapeutics stock on 19 May 2020 worth over 8,963,250$. On average, Ventures trades about 213,333 units every 9 days since 2020. As of 16 June 2020 Ventures still owns at least 313,497 units of Aprea Therapeutics stock.

You can see the complete history of Ventures In stock trades at the bottom of the page.

Insiders trading at Aprea Therapeutics

Over the last 5 years, insiders at Aprea Therapeutics have traded over 63,126,246$ worth of Aprea Therapeutics stock and bought 2,073,560 units worth 29,606,912$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Vantage I, L.P.Versant Vant...、John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of 420,918$. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth 7,363$.

What does Aprea Therapeutics do?

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Complete history of Ventures In stock trades at Aprea Therapeutics

Aprea Therapeutics executives and stock owners

Aprea Therapeutics executives and other stock owners filed with the SEC include:

• Christian Schade,
  Chairman of the Board, President, Chief Executive Officer
• Scott Coiante,
  Chief Financial Officer, Senior Vice President, Secretary
• Eyal Attar,
  Senior Vice President, Chief Medical Officer
• Christian S. Schade,
  Pres, CEO & Chairman
• Dr. Eyal C. Attar M.D.,
  Sr. VP & Chief Medical Officer
• Scott M. Coiante,
  Sr. VP, Company Sec. & CFO
• John Henneman,
  Lead Independent Director
• Bernd Seizinger,
  Independent Director
• Guido Magni,
  Independent Director
• Johan Christenson,
  Independent Director
• Dr. Oren Gilad Ph.D.,
  Co-Founder, Pres & Director
• Richard Peters,
  Director
• Fouad Namouni,
  Director
• Michael Kelly,
  Director
• Gregory Wessels,
  Chief Commercial Officer
• Gregory Korbel,
  Vice President - Business Development
• Lars Abrahmsen,
  Senior Vice President, Chief Scientific Officer
• Andrea Epstein,
  Controller
• Dr. Michel Afargan Ph.D.,
  Head of Pharmacology Devel.
• Hank Breslin,
  Head of Medicinal Chemistry
• Dr. Rifat Pamukcu M.D.,
  Chief Medical Advisor & Director
• Dr. Dansu Li Ph.D.,
  Head of Technology
• Dr. Lars B. Abrahmsen,
  Sr. VP & Chief Scientific Officer
• Dr. Gregory A. Korbel Ph.D.,
  Sr. VP & Chief Bus. Officer
• Ventures Iv, L.P.5 Am Co In...,
  
• Marc Duey,
  Director
• Michael Grissinger,
  Director
• Rifat Pamukcu,
  Director
• Ventures Iv, L.P.5 Am Co In...,
  
• V Luxco S.A R.L.Versant Ven...,
  
• Oren Gilad,
  President, CEO
• Investments Ab Karolinska D...,
  
• Scott M Rocklage,
  Director
• V Luxco S.A R.L.Versant Ven...,
  
• Vantage I, L.P.Versant Vant...,
  
• Group, Llc Green Jeremy Red...,
  
• Vii, L.P.Health Cap Vii Gp ...,
  
• Jonathan Hepple,
  
• John P. Hamill,
  SrVP/CFO/Prin Fin & Acct Ofcr
• Gabriela Gruia,
  Director
• Jean Pierre Bizzari,
  Director
• Nadeem Q. Mirza,
  Chief Medical Officer